Tirzepatide, A New Dual-action Type 2 Diabetes Drug, Showed Better Weight L

https://www.astersteroids.com/tirzepatide-a-new-du , al-action-type-ii-
diabetes-drug-showed-better- , weight-loss-results-than-semaglultide/
Purity:9 , 8% HPLC
Packing:2mg/vial and 5mg/vial;10vials/box
Min Order: 1box
Payment:Bitcoin,Moneygram and Wester Union
Lead time:24hours after received payment
Safe shipping to US and most of Europe country
Storage:Shading, confined preservation,2-8°C

Tirzepatide is a drug approved for medical use in the United States,
European Union, Canada and Australia for the treatment and control of type 2
diabetes mellitus. As a dual GIP and GLP-1 receptor agonist, it is the first
of its kind.

What is Tirzepatide for Type 2 Diabetes?
The incidence of type 2 diabetes has been on the rise worldwide in recent
years, with about 420 million adults worldwide, 30 million people in the
United States and 114 million people in China having type 2 diabetes.
Globally, one person dies every six seconds from complications related to
type 2 diabetes. Type 2 diabetes is the eighth leading cause of death in the
world.

Obesity and overweight are important risk factors for type 2 diabetes, and
about 80-90% of type 2 diabetes patients are overweight or obese.

Type 2 diabetes mellitus, also known as non-insulin-dependent diabetes
mellitus, is a chronic metabolic disease characterize by pancreatic beta
cell dysfunction and insulin resistance. Treatment for this disease focuses
on controlling blood sugar, improving insulin resistance and protecting
pancreatic beta cell function. The main methods are insulin therapy, oral
hypoglycemic drugs, diet control and exercise.

A number of drugs used to treat type 2 diabetes are GLP-1 agonists,
including Wegovy, Ozempic (Semaglutide), Rybelsus, Saxenda,
Trulicity(Dulaglutide) .Peptides Tirzepatide is the latest drugs to treat
type 2 diabetes.

What is GLP-1?
Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone that promotes
insulin secretion. It has the ability to reduce blood glucose levels in a
glucose-dependent manner by enhancing insulin secretion.

Natural GLP-1 is usually secrete in the gut after eating. It is susceptible
to amidation and proteolytic cleavage and is broken down rapidly in the
body, resulting in a known half-life of about 2 minutes. As a result, only
10% to 15% of GLP-1 enters the cycle in its entirety. To overcome this
problem, They develop GLP-1 receptor agonists to increase GLP-1 activity.

By activating GLP-1 receptor or prolonging the action time of GLP-1, GlP-1-
based therapeutic drugs have the multi-effect mechanism of promoting β-cell
generation and secretion of insulin, inhibiting α-cell secretion of
glucagon, delaying gastric emptying and inhibiting appetite. To control
blood sugar levels. At the same time, GLP is glucose-dependent and does not
cause severe hypoglycemic symptoms.

What is Tirzepatide wight loss?
Tirzepatide basic information

Cas No.:2023788-19-2

MF:C225H348N48O68

M , W: 4813.527

Bioavailability: 80%

Route of administration: subcutaneous

Elimination half-life: 5 days

Tirzepatide, also known as LY3298176, or Mounjaro, is a linear polypeptide
composed of 39 amino acids that has been chemically modified by lipylation
to improve its uptake into cells and metabolic stability. In structure,
Tirzepatide is an analogue of GIP. Fatty acids are attached to the base of
GIP, thus having a longer half-life and higher affinity with albumin.

Tirzepatide is a new type II diabetes drug. As an analog of GIP, Tirzepatide
plays the similar role of GIP. At the same time, it is also a GLP-1 receptor
agonist, which has the dual effects of lowering blood glucose and promoting
gastrointestinal function, as well as promoting weight loss.

Minimum Order: 11111 grams

Click to Enlarge